Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2021 ...
05 March 2021 - 12:00AM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused
on developing FT218, an investigational, once-nightly formulation
of sodium oxybate designed to treat excessive daytime sleepiness
and cataplexy in adults with narcolepsy, today announced that it
entered into an exclusive collaboration with the American Academy
of Sleep Medicine Foundation (AASM Foundation) to support its 2021
Young Investigators Research Forum. The forum, taking place
virtually through August, will provide scholarships and research
training to 24 early career sleep medicine researchers.
The Young Investigators Research Forum is a unique annual
training program that was first launched in 2009, and it provides
intense career-building and networking opportunities for top sleep
investigators in the U.S. who are starting their careers in sleep
and circadian research. The program aims to provide trainees with
the necessary skills for a productive and successful career,
including learning about various funding opportunities, refining
research ideas and understanding grant review processes. Trainees
will work alongside and learn from other industry professionals to
develop a deeper understanding of their role in shaping the future
of sleep mechanisms.
“Avadel is delighted to join the AASM Foundation in its mission
to provide educational resources and training to further develop
the research careers of sleep scientists, including these 24
deserving trainees,” said Jennifer Gudeman, PharmD, Vice President
of Medical and Clinical Affairs at Avadel. “Research in sleep
health is critical to improving the overall wellbeing of people
living with sleep disorders, including narcolepsy. Avadel is proud
to support and invest in the next generation of sleep specialists,
empowering them to advance this important field of medicine.”
AASM Foundation President Anita V. Shelgikar, MD, MHPE added,
“We welcome Avadel’s support on the 2021 Young Investigators
Research Forum and we appreciate their commitment to investing in
the future of sleep research and sleep medicine. Avadel’s
contributions directly support the AASM Foundation’s efforts to
establish new awards and initiatives that promote discoveries to
advance the understanding of sleep for healthier lives.”
To learn more about the 2021 Young Investigators Research Forum,
please visit: https://bit.ly/3qEK1c1
About Avadel Pharmaceuticals plc:Avadel
Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company
primarily focused on the development and FDA approval of FT218, an
investigational, once-nightly formulation of sodium oxybate
designed to treat excessive daytime sleepiness and cataplexy in
adults with narcolepsy. For more information, please visit
www.avadel.com.
About the American Academy of Sleep Medicine
Foundation:Founded in 1998, the AASM Foundation is a
not-for-profit 501(c)(3) charitable and scientific organization
that was established by the American Academy of Sleep
Medicine. The AASM Foundation has invested in the future of sleep
medicine by supporting more than 240 awards totaling $19 million in
funding. The AASM Foundation’s portfolio includes research awards
for all career stages, community awards and training awards. For
more information, please visit foundation.aasm.org.
Contacts:Avadel Media
ContactPatrick BurseyLifeSci
Communications, LLCPhone: (646) 970-4688Email:
pbursey@lifescicomms.com
AASM Foundation Media RelationsPhone: (630)
737-9700Email: media@aasm.org
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Apr 2024 to May 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From May 2023 to May 2024